S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 

Werewolf Therapeutics Stock Price, News & Analysis (NASDAQ:HOWL)

$2.90
-0.02 (-0.68%)
(As of 12/8/2023 ET)
Compare
Today's Range
$2.85
$2.96
50-Day Range
$1.78
$3.17
52-Week Range
$1.55
$4.57
Volume
33,597 shs
Average Volume
138,213 shs
Market Capitalization
$104.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.58

Werewolf Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
264.7% Upside
$10.58 Price Target
Short Interest
Healthy
2.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.05mentions of Werewolf Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.03) to ($1.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

238th out of 954 stocks

Pharmaceutical Preparations Industry

60th out of 362 stocks


HOWL stock logo

About Werewolf Therapeutics Stock (NASDAQ:HOWL)

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an IL-21 INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

HOWL Stock Price History

HOWL Stock News Headlines

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Biotech Soars On New Price Target And Analyst Rating
See More Headlines
Receive HOWL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
12/09/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/28/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HOWL
Fax
N/A
Employees
46
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.58
High Stock Price Target
$15.00
Low Stock Price Target
$8.30
Potential Upside/Downside
+264.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-53,810,000.00
Net Margins
-144.98%
Pretax Margin
-144.98%

Debt

Sales & Book Value

Annual Sales
$25.73 million
Book Value
$3.98 per share

Miscellaneous

Free Float
26,746,000
Market Cap
$104.96 million
Optionable
Not Optionable
Beta
0.18
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Daniel J. Hicklin Ph.D. (Age 59)
    Founder, CEO, President, Secretary & Director
    Comp: $817.31k
  • Dr. Cynthia Seidel-Dugan Ph.D. (Age 64)
    Chief Scientific Officer
    Comp: $600.35k
  • Dr. Randi Isaacs M.D. (Age 67)
    Chief Medical Officer
    Comp: $637.15k
  • Mr. Timothy W. Trost CPA (Age 65)
    CFO, Treasurer & Assistant Secretary
    Comp: $511.88k
  • Dr. Chulani Karunatilake Ph.D. (Age 64)
    Chief Technology Officer
    Comp: $343.43k
  • Ms. Ellen A. Lubman M.B.A. (Age 47)
    Chief Business Officer














HOWL Stock Analysis - Frequently Asked Questions

Should I buy or sell Werewolf Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Werewolf Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HOWL shares.
View HOWL analyst ratings
or view top-rated stocks.

What is Werewolf Therapeutics' stock price target for 2024?

3 brokerages have issued 1-year price targets for Werewolf Therapeutics' stock. Their HOWL share price targets range from $8.30 to $15.00. On average, they anticipate the company's share price to reach $10.58 in the next year. This suggests a possible upside of 264.7% from the stock's current price.
View analysts price targets for HOWL
or view top-rated stocks among Wall Street analysts.

How have HOWL shares performed in 2023?

Werewolf Therapeutics' stock was trading at $2.05 at the start of the year. Since then, HOWL shares have increased by 41.5% and is now trading at $2.90.
View the best growth stocks for 2023 here
.

Are investors shorting Werewolf Therapeutics?

Werewolf Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 518,500 shares, an increase of 62.8% from the October 31st total of 318,400 shares. Based on an average daily volume of 827,000 shares, the days-to-cover ratio is presently 0.6 days. Currently, 2.3% of the shares of the company are short sold.
View Werewolf Therapeutics' Short Interest
.

When is Werewolf Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our HOWL earnings forecast
.

How were Werewolf Therapeutics' earnings last quarter?

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) issued its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.04. The firm had revenue of $5.90 million for the quarter, compared to analyst estimates of $15.60 million. Werewolf Therapeutics had a negative net margin of 144.98% and a negative trailing twelve-month return on equity of 31.44%.

When did Werewolf Therapeutics IPO?

(HOWL) raised $101 million in an IPO on Friday, April 30th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

Who are Werewolf Therapeutics' major shareholders?

Werewolf Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Schonfeld Strategic Advisors LLC (0.49%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bioventures 2014 LP Mpm, Ra Capital Management, LP and Reid Leonard.
View institutional ownership trends
.

How do I buy shares of Werewolf Therapeutics?

Shares of HOWL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:HOWL) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -